Opendata, web and dolomites

SIME-LMT

Development of a digital diagnostics rapid Lung Maturity Test (LMT) for premature infants, to assist neonatologists in the diagnosis of Respiratory Distress Syndrome at birth

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SIME-LMT project word cloud

Explore the words cloud of the SIME-LMT project. It provides you a very rough idea of what is the project "SIME-LMT" about.

worldwide    intensive    aligned    infant    stay    improves    business    biological    generating    5m    ventilation    protocol    laboratory    hospital    maturity    sime    chemistry    initial    60    sciences    bodily    refining    diagnostic    optimal    400    innovation    representing    annum    predicts    lung    nicus    treatment    quick    expertise    chemometrics    point    cloud    risk    platform    samples    healthcare    life    opportunity    days    2000    95    preventative    diagnostics    neonatal    375m    data    approx    profit    time    fluid    revenue    clinical    minutes    complexity    mechanical    birth    tests    rds    small    4bn    syndrome    patient    providers    attaining    validation    distress    reduce    software    lmt    care    savings    total    valuation    market    faster    driving    strategy    reduces    oxygen    916    company    digitising    60m    outcomes    digital    prototype    gt    standard    accuracy    neonatologists    diagnosis    respiratory    prevented   

Project "SIME-LMT" data sheet

The following table provides information about the project.

Coordinator
SIME DIAGNOSTICS LIMITED 

Organization address
address: Stevenage Bioscience Catalyst, Gunnel Wood Road
city: STEVENAGE
postcode: SG1 2FX
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.simelmt.com
 Total cost 3˙417˙674 €
 EC max contribution 2˙864˙455 € (84%)
 Programme 1. H2020-EU.3.1. (SOCIETAL CHALLENGES - Health, demographic change and well-being)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-2-2014
 Funding Scheme SME-2
 Starting year 2015
 Duration (year-month-day) from 2015-04-01   to  2017-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SIME DIAGNOSTICS LIMITED UK (STEVENAGE) coordinator 2˙864˙455.00

Map

 Project objective

SIME LMT will develop a simple digital, software and cloud-based diagnostic test to analyse very small samples of bodily fluid at point of care that predicts the risk of an infant developing Respiratory Distress Syndrome (RDS) within 10 minutes of birth. The platform will offer neonatologists more control through greater accuracy and faster results so they can deliver optimal patient care and improve clinical outcomes. Such technology has not been deployed before in healthcare diagnostics because of the complexity of the required knowledge and expertise in the field of chemometrics. RDS can only be prevented by a quick diagnosis of lung maturity and treatment at birth.

We have developed a working prototype test that measures within 95% of the established laboratory and chemistry validation methods. We are currently refining the method in a pre-clinical test which will provide test validation data and demonstrate that the test improves clinical outcomes and enables change in clinical practice from the current treatment standard to a preventative treatment protocol which reduces RDS i.e. generating Level 4 – Level 1 evidence.

Our initial target market is the NICUs: 2000 in the US and 1,400 in the EU, where there is an estimated market of 916,000 tests and a revenue potential of approx. €375m per annum. SIME Diagnostics also has the potential to reduce neonatal intensive care treatment including mechanical ventilation by 60%, less time on oxygen and hospital stay by 10 days. The overall savings opportunity has been estimated to be more than €3.4bn total, and €1.5m per 100 cases representing a cost savings and profit making opportunity for healthcare providers worldwide. The project is well aligned with our business growth strategy which is aimed at growing the business through digitising biological information, driving innovation in life sciences and healthcare. Attaining level 1 clinical evidence will increase company valuation to >€60m.

 Deliverables

List of deliverables.
Approved publication Documents, reports 2019-05-30 11:42:35
Project Specific Website Other 2019-05-30 11:42:34
Production tooling, sample batch (spectrometers) Demonstrators, pilots, prototypes 2019-05-30 11:42:35

Take a look to the deliverables list in detail:  detailed list of SIME-LMT deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SIME-LMT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SIME-LMT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.;H2020-EU.2.3.1.)

PREPARE (2016)

Preventing Respiratory Events through Proactive Assessment of Respiratory Effort

Read More  

SIME-LMT (2015)

Development of a digital diagnostics rapid Lung Maturity Test (LMT) for premature infants, to assist neonatologists in the diagnosis of Respiratory Distress Syndrome at birth

Read More  

ADVANTAGE (2015)

ADvanced Validation of A Novel TB Active disease diagnostic to address Global unmet needs: a European consortium approach

Read More